Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus Lifesciences Ltd soars 2.1%
Zydus Lifesciences Ltd is quoting at Rs 1012.55, up 2.1% on the day as on 12:49 IST on the NSE. The stock is up 12.17% in last one year as compared to a 4.94% drop in NIFTY and a 13.93% drop in the Nifty Pharma index.
Five Stocks To Buy: NMDC, Tata Steel, Varun Beverages And More | May 15, 2026
Top picks include a consensus buy on NMDC, alongside Zydus Lifesciences, Varun Beverages (VBL), Max Healthcare, and Tata Steel.
Market Trading Guide: Buy Zydus Lifesciences, Solar Industries on Friday for gains up to 15%
Nifty 50 closed higher for a second straight session, driven by banking, metal and pharma stocks despite IT weakness. Analysts see 23,800 as a crucial resistance level, while recommending Zydus Lifesciences and Solar Industries India for near-term gains on strong technical indicators and bullish momentum.
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition
Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus announced a $166 million acquisition of US-based Assertio. Investor sentiment improved on expectations of capital return and strategic business expansion.
Zydus Lifesciences jumps 5% as board to consider buyback, results on May 19
The buying on the counter came after the company, through a filing, said that its board will consider a buyback in a meeting along with the financial results on Tuesday, May 19, 2026
Stocks to watch: HAL, IRFC, Bharti Airtel, Zydus Lifesciences among 10 shares in focus today - Mint
Stocks to watch: HAL, IRFC, Bharti Airtel, Zydus Lifesciences among 10 shares in focus todayMint
Here's why today and May 19 are important sessions for Zydus Life shareholders
Zydus Lifesciences will acquire Assertio Holdings for $23.5 per share in cash, valuing the transaction at $166.4 million. Assertio is a US-based specialty pharmaceutical company with a focus on oncology and pain management.
Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata Motors
Indian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. Zydus Lifesciences is nearing a US acquisition, while Maruti Suzuki commits to green logistics.
Zydus Lifesciences may buy back shares; board meeting scheduled on May 19
Zydus Lifesciences said its board will consider a share buyback proposal on May 19, with the stock trading slightly higher on the NSE.
Zydus Lifesciences Ltd rises for third straight session
Zydus Lifesciences Ltd is quoting at Rs 934.15, up 2.4% on the day as on 12:49 IST on the NSE. The stock is up 5.42% in last one year as compared to a 1.62% slide in NIFTY and a 12.19% slide in the Nifty Pharma index.
Zydus Lifesciences in focus after USFDA clears Ahmedabad plant, Aflibercept biosimilar launch
Zydus Lifesciences is in focus after receiving USFDA clearance with zero observations for its Ahmedabad facility and launching ANYRA, India’s first indigenous Aflibercept biosimilar. The developments strengthen its regulatory standing and expand its ophthalmology portfolio, positioning the company to tap into a large and growing domestic market for retinal therapies.
Stocks to Watch for Feb 19: Zydus Life, TVS Motor, NCC, Jindal Saw and more
From NCC and its step-down subsidiary OB Infrastructure receiving an order of debarment from the NHAI to Zydus Lifesciences getting final approval from the USFDA for bosentan tablets for oral suspension, these are some of the stocks to watch out ahead of Thursday's trading session.